This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
To participate in the study voluntarily and sign the informed consent (ICF), with good compliance and cooperative visits;
Patients must be ≥ 18 years of age (Based on the date of signing the informed Consent (ICF));
Follicular lymphoma (FL);
Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome (CLL/SLL or RS);
Female subjects who are pregnant or breastfeeding;
Estimated lifetime is less than 3 months;
In the investigator's judgment, patients who require but are unable to receive prophylactic treatment for Pneumocystis or herpes simplex virus (HSV) prior to trial drug treatment;
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function;